News Cantargia AB

Equities

CANTA

SE0006371126

Market Closed - Nasdaq Stockholm Other stock markets 11:29:39 2024-04-16 am EDT			5-day change	1st Jan Change
3.82 ^SEK	+4.66%		-12.14%	+2.19%

Apr. 10	Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal	CI
Apr. 08	Cantargia AB Presents Unique Effects of Nadunolimab in Pancreatic Cancer	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cantargia AB Publishes Preclinical Data on the Potential of CAN10 in Systemic Sclerosis in A Leading Scientific Journal	Apr. 10	CI
Cantargia publishes preclinical data on the potential of CAN10 in systemic sclerosis in a leading scientific journal	Apr. 10	AQ
Cantargia AB Presents Unique Effects of Nadunolimab in Pancreatic Cancer	Apr. 08	CI
Cantargia presents unique effects of nadunolimab in pancreatic cancer	Apr. 08	AQ
Cantargia Publishes Data Highlighting the Potential of CAN10 in Atherosclerosis	Apr. 02	CI
Cantargia publishes data highlighting the potential of CAN10 in atherosclerosis	Apr. 02	AQ
Cantargia reports progress towards start of DOD-sponsored clinical trial of nadunolimab in leukemia	Mar. 27	AQ
Cantargia AB Reports Progress Towards Start of DOT-Sponsored Clinical Trial of Nadunolimab in Leukemia	Mar. 27	CI
Cantargia Reports New Data Highlighting Potential of CAN10 Antibody, Currently in Phase I Clinical Development, as Therapy in Systemic Sclerosis	Mar. 14	CI
Cantargia presents new human data further supporting CAN10 in the treatment of systemic sclerosis	Mar. 14	AQ
Cantargia Reports New Preclinical Data on Antitumor Effects of nadunolimab in Pancreatic Cancer	Mar. 05	CI
Cantargia reports new preclinical data on antitumor effects of nadunolimab in pancreatic cancer	Mar. 05	AQ
Cantargia Q4 2023 - Progress with CAN10 and in PDA	Feb. 23	AQ
Transcript : Cantargia AB, 2023 Earnings Call, Feb 22, 2024	Feb. 22
Cantargia publishes Year-End Report for 2023	Feb. 22	AQ
Cantargia Secures US Approval to Start Patient Recruitment for Pancreatic Cancer Therapy	Feb. 20	MT
Cantargia Reports US Regulatory Approval to Start Pancreatic Cancer Phase IIB Trial with Nadunolimab	Feb. 20	CI
Cantargia reports US regulatory approval to start pancreatic cancer phase IIb trial with nadunolimab	Feb. 20	AQ
Cantargia reports new data reinforcing nadunolimab as cancer combination therapy	Feb. 12	AQ
Cantargia Reports New Data Reinforcing Nadunolimab as Cancer Combination Therapy	Feb. 12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Cantargia AB

Equities

CANTA

SE0006371126

Summary

Filters